Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05310448 · ClinicalTrials.gov registry record · NA
Tumor Treating Fields for the Treatment of Brainstem Gliomas
A NA study of Glioma, sponsored by Emory University.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT05310448: Recruiting NA study of Glioma, sponsored by Emory University.
NCT05310448 is a NA study of Glioma that is actively recruiting participants, run by Emory University. The registered enrollment target is 10 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05310448, a NA study of Glioma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with cancer cell division. TTFields may prevent growth or decrease size of gliomas in patients
Primary Outcome
Adverse event rates will be summarized descriptively using frequencies and percentages in addition to a tolerability rate defined as composite of any dose-limiting toxicity.
Conditions Studied
Interventions
- DEVICE Optune device
Study Locations (3)
Georgia
- Emory Proton Therapy Center - Atlanta
- Emory University/Winship Cancer Institute - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2027-05-01 |
| Phase | NA |
What NCT05310448 shows while recruiting
NCT05310448 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which Optune device is the first listed.
NCT05310448 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05310448 about?
NCT05310448 is a clinical study titled "Tumor Treating Fields for the Treatment of Brainstem Gliomas". This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with can...
What is the current status of trial NCT05310448?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2022-05-11. Estimated completion is 2027-05-01.
What conditions does trial NCT05310448 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT05310448?
The interventions under investigation include: Optune device (DEVICE).
Who is sponsoring clinical trial NCT05310448?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05310448 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05310448's enrollment target sits among peer trials
10 79th of 87 higher than 6 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ASCENT Intervention for Brain Tumor Patients
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
-
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI